Notably, NRP1flflNRP2flfl.ECKO tumors also exhibited significantly less vasculature than either NRP1flfl.ECKO or NRP2flfl.ECKO tumors (Fig. 1F and G), suggesting that the dual targeting of both NRP1 and NRP2 elicits a compounded antiangiogenic response to inhibit tumor development and growth. The gene discussed is NRP1; the disease is neoplasm.